Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to evaluate the safety and efficacy of IQP-PO-101 in regulating the bowel movement frequency
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IQP-PO-101 | Experimental | Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| IQP-PO-101 | Device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Bowel movement frequency | Subjects will keep a record of the number of bowel movements, if any, from 00:00 hours to 23:59 hours (midnight to midnight) daily. | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Bristol Stool Form Scale | Subjects will keep a record of their stool form, for each bowel movement. | 6 weeks |
| Straining at the start/ end of defecation | On a 100mm visual analogue scale (VAS), subjects will rate their feeling of straining at the start/ end of defecation for each bowel movement. |
Not provided
Inclusion Criteria:
A subject must have experienced 2 - 4 bowel movements per week and at least 2 of the following symptoms over the preceding 3 months (self-reported):
Recorded between 4 and 9 defecations in the 14-day bowel movement diary during the run-in period
Subjects of childbearing potential must agree to use appropriate contraceptive methods during run-in and treatment period
Commitment to avoid the use of any laxatives and/ or other medicinal products/ supplements that may interfere with bowel movement frequency during the run-in and treatment period
Written informed consent.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Analyze & Realize Ag | Berlin | State of Berlin | 10369 | Germany |
Not provided
| ID | Term |
|---|---|
| D003248 | Constipation |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 weeks |
| Pain during defecation | On a 100mm visual analogue scale (VAS), subjects will rate their pain during defeca-tion for each bowel movement. | 6 weeks |
| Feeling of incomplete evacuation | With each bowel movement, subjects will mark "Yes" or "No" to indicate whether there was a feeling of incomplete evacuation. | 6 weeks |
| Evaluation of efficacy by subjects | The subjects evaluate independently the efficacy of the investigational device (global scaled evaluation with "very good", "good", "moderate" and "poor"). | 4 weeks |
| Evaluation of efficacy by investigator | The investigator evaluates independently the efficacy of the investigational device (global scaled evaluation with "very good", "good", "moderate" and "poor") | 4 weeks |
| Full blood count | Venous blood samples are obtained at screening and the end of the treatment period (4 weeks) | 4 weeks |
| Clinical chemistry | Venous blood samples are obtained at screening and the end of the treatment period (4 weeks) for measurements of uric acid, HbA1c and lipid profiles. An analysis will be done based on the change between the 2 periods. | 4 weeks |
| Safety evaluation by subjects | The subjects evaluate independently the safety of the investigational device (global scaled evaluation with "very good", "good", "moderate" and "poor") | 4 weeks |
| Safety evaluation by investigators | The investigators evaluate independently the safety of the investigational device (global scaled evaluation with "very good", "good", "moderate" and "poor") | 4 weeks |
| Adverse events | 6 weeks |